NewBay Pharma

Executive Summary

NewBay Pharma is a preclinical-stage biotechnology company focused on combating antimicrobial resistance (AMR) through the discovery of novel small-molecule antibiotics. Based in Nanjing, China, the company targets multi-drug resistant bacterial infections by developing compounds with new mechanisms of action. Despite the global urgency for new antibiotics, the company remains at an early stage with no disclosed pipeline assets or funding information. The preclinical nature and lack of public data introduce significant uncertainty, though the addressable market and unmet need in AMR are substantial. NewBay's success hinges on advancing its lead candidates into IND-enabling studies and securing partnerships or funding to support clinical development.

Upcoming Catalysts (preview)

• Q2 2027Lead Optimization Completion60% success
• Q4 2027IND-Enabling Studies Initiation40% success
• TBDStrategic Partnership or Licensing Deal30% success